Impact of Long Term of Benzodiazepine Use on Psychiatric Manifestation

Overview

Benzodiazepines are usually a secondary drug of abuse-used mainly to augment the high received from another drug or to offset the adverse effects of other drugs. Few cases of addiction arise from legitimate use of benzodiazepines. Pharmacologic dependence, a predictable and natural adaptation of a body system long accustomed to the presence of a drug, may occur in patients taking therapeutic doses of benzodiazepines. However, this dependence, which generally manifests itself in withdrawal symptoms upon the abrupt discontinuation of the medication, may be controlled and ended through dose tapering, medication switching, and/or medication augmentation. Due to the chronic nature of anxiety, long-term low-dose benzodiazepine treatment may be necessary for some patients; this continuation of treatment should not be considered abuse or addiction. previous study reported that The results of the study are important in that they corroborate the mounting evidence that a range of neuropsychological functions are impaired as a result of long-term benzodiazepine use, and that these are likely to persist even following withdrawal. The findings highlight the residual neurocognitive compromise associated with long-term benzodiazepine therapy as well as the important clinical implications of these results.

Full Title of Study: “Impact of Long Term of Benzodiazepine Use on Psychiatric Manifestation in Neuropsychiatric Disease”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: June 20, 2022

Interventions

  • Behavioral: Detailed interview with personal demographic data
    • , such as age, sex, education, history of occupation, past medical history, family history, medical, neurological, and psychiatric disorders.
  • Behavioral: Intelligence assessment using the Arabic version of the Wechsler Adult Intelligence Scale (WAIS)
    • the test consists of six verbal subtests and five performance subtests. It used in measure Intelligence
  • Behavioral: The Arabic version of the Structured Interview for the Five-Factor Personality Model (SIFFM)
    • it depend on a model of general language personality descriptors that based on theory suggests five broad dimensions to describe human personality
  • Behavioral: the Hamilton Depression Rating Scale
    • it used for evaluation depression severity. It is 17 items and each item’s score (0-4). with a total score range of 0-54
  • Behavioral: The Hamilton Anxiety Rating Scale
    • it used for evaluation the severity of anxiety. The scale consists of 14 items and each item is scored on a scale from 0 to 4 , with a total score range of 0-56
  • Behavioral: The Minnesota Multiphasic Personality Inventory-2 (MMPI-2)
    • It used to evaluate range of symptoms of psychopathology and personality traits that are maladaptive. It has 10 clinical scales subscales included the following: 1, hypochondriasis (Hs); 2, depression (D); 3, hysteria (Hy); 4, psychopathic deviation (Pd); 5, masculinity-femininity (Mf); 6, paranoia (Pa); 7, psychophrenia (Pt); 8, schizophrenia (Sc); 9, hypomania (Ma); 10, social introversion (Ma); (Si). More than 65 responses were considered symptomatic

Clinical Trial Outcome Measures

Primary Measures

  • measure the prevalence of DSM 5 psychiatric disorders associated with long term of benzodiazepine use
    • Time Frame: through study completion, an average of 1 year
  • measure of risk factor of DSM 5 psychiatric disorders associated with long term of benzodiazepine use
    • Time Frame: through study completion, an average of 1 year

Participating in This Clinical Trial

Inclusion Criteria

  • age from 18 years to 50 years – No history of neurological or medical illness Exclusion Criteria:

  • intelligence score more than 80

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Assiut University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Gellan Karamalllah Ramadan Ahmed, lecturer, resarcher OF Neurology and Psychiatry department – Assiut University
  • Overall Contact(s)
    • gellan Ahmed, +201093663928, gillankaram@aun.edu.eg

Citations Reporting on Results

Shinfuku M, Kishimoto T, Uchida H, Suzuki T, Mimura M, Kikuchi T. Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. Int Clin Psychopharmacol. 2019 Sep;34(5):211-221. doi: 10.1097/YIC.0000000000000276.

O'brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66 Suppl 2:28-33.

Crowe SF, Stranks EK. The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis. Arch Clin Neuropsychol. 2018 Nov 1;33(7):901-911. doi: 10.1093/arclin/acx120.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.